This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mondi, M. M. Articles by Levine, E. A. Search for Related Content PubMed PubMed Citation Articles by Mondi, M. M. Articles by Levine, E. A.

Sentinel Lymph Node Biopsy During Pregnancy: Initial Clinical Experience

¹ Surgical Oncology Services, Wake Forest University, Winston-Salem, North Carolina, USA
² East Carolina University, Greenville, North Carolina, USA
³ University of North Carolina, Chapel Hill, North Carolina, USA

Correspondence: Address correspondence and reprint requests to: Edward A. Levine, MD, Surgical Oncology Service, Wake Forest University, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA; E-mail: elevine{at}wfubmc.edu

The diagnosis of breast cancer or melanoma in a pregnant patient presents some unique and difficult challenges for both patients and providers. Lymphatic mapping and sentinel lymph node (SLN) biopsy has become an attractive alternative to elective lymphadenectomy procedures for patients with breast cancer and melanoma. However, there is no data on the safety or utility of sentinel node mapping in pregnant patients. Therefore, we reviewed our experience with mapping in gravid patients. Academic institutions throughout North Carolina were asked to contribute cases of mapping performed during pregnancy. A total of nine women underwent sentinel node mapping during pregnancy. All nine were Caucasian with an average age of 32. SLN were found in all cases and mapping procedures were for breast cancer (three), and melanoma (six). There were no adverse reactions to the SLN procedures and one patient developed a seroma at a biopsy site. All went on to have term deliveries without known adverse effects.

This limited experience shows that SLN mapping procedures are feasible in pregnant patients. However, this is not a general endorsement of such procedures in pregnant patients. We suggest that potential risks of vital dye or radioactive tracers be clearly explained to the parents when the mother is a candidate for a mapping procedure, and be balanced against the risk of delaying therapy or omitting nodal staging.

Key Words: Sentinel node mapping • Pregnancy • Safety • Melanoma • Breast cancer